Onderneming Xtl Biopharma TEL AVIV STOCK EXCHANGE
Aandelen
IL0010854979
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 30-12-14 |
Itay Weinstein
DFI | Director of Finance/CFO | 52 | 01-01-99 |
Doron Turgeman
CHM | Chairman | 56 | 30-12-14 |
Daphna Paran
CTO | Chief Tech/Sci/R&D Officer | - | 04-03-16 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 30-12-14 |
Director/Board Member | 57 | 29-01-20 | |
Director/Board Member | 53 | 01-04-17 | |
Doron Turgeman
CHM | Chairman | 56 | 30-12-14 |
Director/Board Member | 46 | 08-12-14 | |
Director/Board Member | 57 | 01-03-15 | |
Director/Board Member | 63 | 08-12-14 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 514 205 799 | 479 737 353 ( 93,30 %) | 0 | 93,30 % |
Bedrijfsgegevens
XTL Biopharmaceuticals Ltd.
26 Ben-Gurion Street
5112001, Ramat Gan
+972 3 611 6600
http://www.xtlbio.com![Adres Xtl Biopharma](https://cdn.zonebourse.com/static/address/10619579.png)
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 46,56 mld. | |
+45,38% | 41,67 mld. | |
+0,69% | 41,16 mld. | |
+30,52% | 32,4 mld. | |
+22,30% | 28,18 mld. | |
-6,35% | 28,1 mld. | |
+49,25% | 14,52 mld. | |
+49,18% | 13,74 mld. | |
+3,45% | 12,17 mld. |